

# Curriculum Vitae and Bibliography

## Roberto A Leon Ferre, MD

### Personal Information

Place of Birth: Guayaquil, Ecuador  
Work Address: Mayo Clinic  
200 First St SW  
Rochester, MN 55905  
Email Address: leonferre.roberto@mayo.edu

### Present Academic Rank and Position

**Instructor of Medicine** - Mayo Clinic College of Medicine and Science 01/01/2017 - Present  
**Assistant Professor of Oncology** - Mayo Clinic College of Medicine and Science 11/01/2017 - Present  
**Associate Program Director** – Advanced Breast Cancer Fellowship, Mayo Clinic, Rochester, Minnesota 2019 – Present  
**Consultant** - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota 06/24/2020 - Present

### Education

Unidad Educativa San Francisco Javier, Guayaquil, Ecuador - Other, Baccalaureate--Chemistry and Biology Services 1995 - 2001  
Universidad Catolica de Santiago de Guayaquil – Facultad de Ciencias Médicas, Guayaquil, Ecuador - MD 2001 - 2007  
University of Iowa Hospitals and Clinics, Iowa City, Iowa - Internship, Internal Medicine 07/2010 - 06/2011  
University of Iowa Hospital and Clinics, Iowa City, Iowa - Residency, Internal Medicine 07/2011 - 06/2013  
University of Iowa Hospitals and Clinics, Iowa City, Iowa - Chief Resident, Internal Medicine 07/2013 - 06/2014  
Mayo Clinic College of Medicine, Rochester, Minnesota – Hematology & Medical Oncology Fellowship 07/01/2014 - 06/30/2017

### Additional Education

The William J. Harrington Medical Training Programs for Latin America and the Caribbean Students, University of Miami School of Medicine, Jackson Memorial Hospital, Miami, Florida 03/2006 - 08/2006  
Methods in Epidemiologic, Clinical and Operations Research (MECOR) Level 1 (of 4). American Thoracic Society, Quinamávida, Chile 10/2007  
Writing for Biomedical Publication Workshop, Grant writers' seminars and workshops, Mayo Clinic, Rochester, MN 03/2016  
14th Annual School of Breast Oncology, Emory University, Atlanta, Georgia 11/2016  
Cancer Biology and Therapeutics: High Impact Cancer Research Program Harvard Medical School 10/2018 – 10-2019  
Molecular Biology in Clinical Oncology Workshop, American Association for Cancer Research, Snowmass Village, CO 07/2019  
Introductory course in Immunology, The American Association of Immunologists, Virtual Participation 07/2020  
SITC Clinical Immuno-Oncology Network (SCION) Workshop, Society for Immunotherapy of Cancer, Virtual Participation event 01/2022

## Certification

### Board Certifications

#### American Board of Internal Medicine (ABIM)

Internal Medicine	2013 - Present
Hematology	2017 - Present
Medical Oncology	2017 - Present

#### Educational Commission for Foreign Medical Graduates (ECFMG)

ECFMG	2009 - Present
-------	----------------

#### United States Medical Licensing Examination (USMLE)

Step I	2008 - Present
Step II Clinical Knowledge	2009 - Present
Step II Clinical Skills	2009 - Present
Step III	2010 - Present

### Other Certifications

#### Mayo Clinic Quality Academy

Mayo Clinic Quality Fellow: Bronze Level Certification	2014
--	------

### Licensure

Iowa	08784 (Medical-Resident)	2010-2014
Minnesota	57809 (Medical)	2014 - Present

### Honors and Awards

<b>Academic Merit Scholarship</b> - Universidad Catolica de Santiago de Guayaquil – Facultad de Ciencias Medicas Scholarship awarded to the top 5% GPA during each medical school semester.	2003 - 2005
<b>Golden Award for Academic Merit</b> - Universidad Catolica de Santiago de Guayaquil – Facultad de Ciencias Medicas Awarded to the top 5% GPA during the preceding academic year.	2005
<b>Silver Award for Academic Merit</b> - Universidad Catolica de Santiago de Guayaquil – Facultad de Ciencias Medicas Awarded to the top 10% GPA during the preceding academic year.	2006
<b>First Place, Clinical Vignette Competition</b> - American College of Physicians, Iowa Chapter	2011
<b>Outstanding Junior Resident</b> - University of Iowa Hospitals and Clinics	2011 - 2012
<b>Chief Resident, Internal Medicine</b> - University of Iowa Hospitals and Clinics, Iowa City, Iowa	07/2013 - 07/2014
<b>Oncology Trainee Travel Award</b> - American Society of Clinical Oncology (ASCO), Conquer Cancer Foundation	2015
<b>Rising Star in Oncology</b> - Society for Translational Oncology Fellow's Forum (STOFF), Durham, North Carolina	2016
<b>Chief Fellow</b> - Division of Hematology/Medical Oncology, Department of Internal Medicine, Mayo Graduate School of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota	07/2016 - 06/2017
<b>Outstanding Hematology-Oncology Trainee</b> - Division of Hematology/Medical Oncology, Department of Internal Medicine, Mayo Graduate School of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota	2017

<b>Oncology Merit Award</b> - Conquer Cancer Foundation, American Society of Clinical Oncology	2017
<b>Internal Medicine Residency Program's Highest Rated Educators</b> - Internal Medicine Residency, Rochester, Minnesota Award given by the Mayo Clinic's Internal Medicine Residency Program to the top 30% of the teaching faculty across specialties	2018
<b>Career Enhancement Program Award</b> - Breast Cancer Specialized Programs of Research Excellence (SPORE), Rochester, Minnesota	2019 - 2021
<b>KL2 Scholar</b> - Mayo Clinic Center for Clinical and Translational Science, Mayo Clinic, Rochester, Minnesota	2019 - 2022
<b>Teacher of the Year</b> - Hematology/Medical Oncology Fellowship Program, Rochester, Minnesota	2020
<b>Teacher of the Year</b> - Mayo Fellow's Association in the Department of Internal Medicine Specialties, Rochester, Minnesota	2020
<b>Teacher of the Year</b> - Hematology/Medical Oncology Fellowship Program, Rochester, Minnesota	2021

## Previous Professional Positions and Major Appointments

<b>Junior House Officer</b> - Dr. Abel Gilbert Ponton Hospital, General Surgery and Orthopedics, Guayaquil, Ecuador	2006 - 2007
<b>Junior House Officer</b> - Matilde Hidalgo de Procel Maternity, Obstetrics and Gynecology, Guayaquil, Ecuador	2007
<b>Rural Physician</b> - Santa Lucia Health Center, Guayas, Ecuador	2008 - 2009
<b>Resident Physician</b> – Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa	2010 - 2013
<b>Associate</b> – Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa	2013 - 2014
<b>Fellow</b> – Division of Hematology, Department of Oncology, Mayo Clinic, Rochester, Minnesota	2014 – 2017
<b>Instructor of Oncology</b> - Mayo Clinic College of Medicine and Science	01/01/2017 - 10/31/2017
<b>Chair</b> – American Society of Clinical Oncology (ASCO) Trainee Council	2017 – 2018
<b>Senior Associate Consultant</b> - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota	07/01/2017 - 06/23/2020

## Professional Memberships and Societies

### Professional Memberships and Services

American College of Physicians (ACP) Associate Member	2010 – 2014
American College of Physicians (ACP) National Medical Student and Resident/Fellow Abstract Competition Reviewer	2014
American Medical Association (AMA) Associate Member	2014 - Present
American Society of Clinical Oncology (ASCO) Associate Member	2014 - Present
American Society of Hematology (ASH) Associate Member	2014 – 2017
American Society of Clinical Oncology (ASCO) Professional Development Committee Member	2014 – 2017
American Society of Clinical Oncology (ASCO) Cancer Education Committee Member	2014 – 2017
American Society of Clinical Oncology (ASCO) Self Evaluation Program	2015

Reviewer	
American Society of Clinical Oncology (ASCO) Medical Student Outreach Committee Member	2016 – 2017
American Association for Cancer Research (AACR) Associate Member	09/2017 – Present
American Society of Clinical Oncology (ASCO) Self Evaluation Program Item Writing Task Force Member	2020 – Present
Society for Immunotherapy of Cancer (SITC) Member	2021 - Present

## Journal Responsibilities

### Journal Other Responsibilities

Journal of Cancer	
Reviewer	2011 – Present
American College of Physicians (ACP) National Medical Student and Resident/Fellow Abstract competition	
Reviewer	2014
American Society of Clinical Oncology Self Evaluation Program (ASCO-SEP) 5th Edition Mock Exam	
Reviewer	2014 - 2018
American Society of Clinical Oncology Cancer Interest Group Abstract Forum	
Reviewer	2017 - 2018
Annals of Oncology	
Reviewer	2019 - Present
Annals of Surgical Oncology	
Reviewer	2016 - Present
Breast Cancer Research	
Reviewer	2017 - Present
Breast Cancer Research and Treatment	
Reviewer	2018 - Present
Breast Cancer: Basic and Clinical Research	
Reviewer	2020 - Present
Breast Cancer: Targets and Therapy	
Reviewer	2020 - Present
British Journal of Cancer	
Reviewer	2020 - Present
Clinical Breast Cancer	
Reviewer	2017 - Present
Clinical Cancer Research	
Reviewer	2019 - Present
ecancer.org	
Reviewer	2018 - Present
JNCI Cancer Spectrum	
Reviewer	2019 - Present
Journal of Oncology	
Reviewer	2019 - Present
Journal of Oncology Practice	
Reviewer	2018 - Present
Journal of the National Cancer Institute	

Reviewer Mayo Clinic Health Letter	2017 - Present
Reviewer PLOS One	2019 - Present
Reviewer Scientific Reports	2019 - Present
Reviewer The Breast	2016 - Present
Reviewer The Medical Letter	2016 - Present
Reviewer The Oncologist	2019 - Present
Reviewer Breast Cancer: Basic and Clinical Research	2020 – Present
Reviewer International Journal of Radiation Oncology, Biology, Physics	2020 – Present
Reviewer International Journal of Cancer Care and Delivery	2021 - Present
Reviewer Breast Cancer, Current Oncology Reports	2021 – Present
Section Editor	2022

## Education Interests and Accomplishments

### Curriculum and Course Development

Internal Medicine Resident Core Conference Curriculum Development Revised, planned, and coordinated core-conference topics for the Internal Medicine Residency for the 2013-2014 academic year. University of Iowa Hospitals and Clinics Iowa City, Iowa	2013 - 2014
2014 Internal Medicine Board Review Course Designed and organized the Internal Medicine Board Review Course for the Department of Internal Medicine University of Iowa Hospitals and Clinics	2013 - 2014
Advanced Medical Oncology Fellowship Developed the program's curriculum, rotation schedule and successfully led recruiting efforts for the inaugural class Breast Cancer Track Rochester, Minnesota	2019 - Present
Breast Medical Oncology Education Chair Oversee the breast cancer educational curriculum of the categorical Hematology/Medical Oncology fellowship Medical Oncology Fellowship Rochester, Minnesota	2019 - Present
American Society of Clinical Oncology Self Evaluation Program Item Writing Task Force Wrote case-based multiple-choice questions and served as peer reviewer for questions from other authors for the ASCO self-assessment programs	2021 - Present

### Teaching

Teaching resident Presented 15 lectures on core internal medicine topics for the third- and fourth-year medical students. Roy J. and Lucille A. Carver College of Medicine, University of Iowa Iowa City, Iowa	2012
---	------

Physical diagnosis course Instructor for 18-hour course on history gathering and physical examination for residents of the Oral & Maxillofacial Surgery, General Dentistry and Periodontics training programs, prior to starting clinical rotations through the Internal Medicine and Anesthesia Departments. University of Iowa Hospitals and Clinics Iowa City, Iowa	2013
Internal Medicine residency diagnostic reasoning conferences Moderator of weekly case-based conferences focused on formulation of differential diagnosis and workup of Internal Medicine conditions. Department of Internal Medicine, University of Iowa Hospital and Clinics Iowa City, Iowa	07/2013 - 06/2014
Clinical and professional skills II course Co-facilitator of small group sessions for first year medical students focused on clinical case oral presentation skills. Roy J. and Lucille Carver College of Medicine, University of Iowa Iowa City, Iowa	2014
Foundation of clinical practice IV course Clinical mentor for 3 medical students and 1 physician assistant student during history-taking and physical exam sessions with simulated and real patients Roy J. and Lucille A. Carver College of Medicine, University of Iowa Iowa City, Iowa	2014 - 2017
Platelet disorders and coagulation medicine 1: Hemostasis Led case-based small group sessions with second year medical students Hematology Course, Mayo Medical School Rochester, MN	2014
Breast Cancer Resident Core Oncology Lectures Quarterly introductory lecture to Breast Cancer for Internal Medicine Residents rotating through Medical Oncology Mayo Clinic, Resident Core Oncology Lecture	03/2018 - Present
Breast Cancer Mayo Clinic Resident Core Oncology Lecture Series Rochester, Minnesota	08/2018
Breast Cancer Fellows Core Oncology Lectures Yearly lecture focused on chemotherapy and HER2-directed therapy for early-stage breast cancer for Medical Oncology fellows Hematology/Oncology Fellowship Program	10/02/2018 - Present
A randomized, double-blind, placebo-controlled trial of oxybutynin for hot flashes Internal Medicine Multidisciplinary Breast Conference Rochester, Minnesota	11/2018
Breast Cancer Board Review Mayo Clinic Hematology/Oncology Fellowship Board Review Series Rochester, Minnesota	12/21/2018 - Present

### Mentorship

Ravi, Praful (Internal Medicine Resident) <b>Description:</b> Abstract and manuscript writing. <b>Current Status:</b> Medical Oncologist at Dana-Farber Cancer Institute; Instructor in Medicine at Harvard Medical School <b>Outcome:</b> Fellowship at Dana-Farber Cancer Institute and accepted consultant position at Dana-Farber Cancer Institute.	06/2016 - 02/2017
(Tschautscher) Kaddoura, Marcella (Internal Medicine Resident) <b>Description:</b> Abstract writing <b>Current Status:</b> Fellow in Hematology and Oncology, Mayo Clinic, Rochester <b>Outcome:</b>	07/2016 - 11/2016
Hoversten, Katherine (Internal Medicine Resident) <b>Description:</b> Abstract writing	08/2016 - 07/2017

**Current Status:** Internal Medicine Consultant

**Outcome:**

Yadav, Siddhartha (Hematology/Oncology Fellow) 10/2017 - Present

**Description:** - Siddhartha Yadav, MD (Hematology/Medical Oncology Fellow)

Preparation of abstracts, manuscripts and a book chapter focused on male breast cancer.

**Current Status:** Senior Associate Consultant in Medical Oncology; Assistant Professor of Medicine and Oncology, Mayo Clinic College of Medicine and Science

**Outcome:**

Anampa-Guzman, Andrea (Medical Student) 06/2018 - Present

**Description:** Planning and execution of two studies assessing the impact of the ASCO-sponsored Oncology Student Interest groups in Latin America, subsequently accepted for oral presentation at the ASCO Annual Medical Student & Resident Abstract Forum, published in the Journal of Global Oncology.

**Current Status:** Research Assistant, Rosswell Park Comprehensive Cancer Center

**Outcome:**

Fuentes Bayne, Harry (Hematology/Oncology Fellow) 05/2019 - Present

**Description:** Research focused on multiplexed tissue analyses in carcinomas of unknown primary

**Current Status:** Hematology/Oncology Fellow; Assistant Professor of Medicine and Oncology, Mayo Clinic College of Medicine and Science

**Outcome:**

Schmidt, Walker M. (Medical Student) 2020 - Present

**Description:** Career Advisor

**Current Status:**

**Outcome:**

Shah, Shiv (Medical Student) 2020

**Description:** Career Advisor

**Current Status:**

**Outcome:**

Weng, Jessica (MD/PhD Student) 2021

**Description:** Career Advisor

**Current Status:**

**Outcome:**

### Academic Career Development

Fellows and Associates as Clinical Educators (FACE) Program 07/2013 - 06/2014

Program designed to introduce future clinician-educators to teaching and educational skills, test question development, clinician mentoring, curriculum and teaching portfolio development, educational research, among others.

Department of Internal Medicine and Office of Consultation and Research in Medical Education, University of Iowa Hospitals and Clinics.

Iowa City, Iowa

Chief Resident Leadership Development Program 07/2013 - 06/2014

Program for chief residents designed to expand insights and skills related to leadership, effective communication, conflict management, change implementation, motivation, teamwork, and organizational culture, among others.

Carver College of Medicine, University of Iowa

Iowa City, Iowa

Society for Translational Oncology Fellows' Forum 12/2016

Three-day intensive forum that brings together a small group of fellows and junior faculty from the leading medical, surgical, radiation, and pediatric oncology fellowship programs, offering opportunities for education, professional development in translational cancer research; research, education, and the science of drug development in oncology; networking and mentorship to guide career development for young oncologists.

Journal of Oncology Practice Reviewer Mentoring Program Program designed to provide training on the peer-review process, by pairing new reviewers with seasoned reviewers.	01/2018 - 01/2019
National Board of Medical Examiners/American Society of Clinical Oncology Question Writing Workshop	11/2021

## **Institutional/Departmental Administrative Responsibilities, Committee Memberships and Other Activities**

### **Mayo Clinic**

Junior Faculty Career Development Committee Chair	2020 - Present
Mayo Clinic Hematology Inpatients Oversight Team, Education Subgroup Committee Member	07/2016 - 06/2017
Mayo Clinic Rochester, Hematology and Oncology Education & Program Evaluation Committee Member	2016 - Present
Mayo Clinic Rochester, Oncology Divisional Education Committee Member	07/2014 - 06/2016
MCCC (Mayo Clinic Cancer Center) Training and Career Enhancement Subcommittee Committee Member	04/30/2021 - Present

### **Activities at Other Institutions**

American Society of Clinical Oncology Professional Development Committee Member	09/2014 - 05/2018
American Society of Clinical Oncology Trainee Council Member	09/2014 - 05/2018
American Society of Clinical Oncology Trainee Council Chair and Member	06/2017 - 05/2018
American Society of Clinical Oncology, Professional Development Committee, Medical Student Outreach Working Group Member	07/2016 - 05/2017

## **Presentations Extramural**

### **National or International**

#### **Invited**

Update on Clinical Trials & Triple Negative Breast Cancer CancerCare Teleconference	12/20/2017
Updates on Triple Negative Breast Cancer Advances in Breast Cancer Management Ponte Vedra Beach, FL, Florida	02/10/2018
Updates in ER-positive, PR-positive, HER2-positive Breast Cancer CancerCare Teleconference	04/18/2018
Breast Cancer and Older Women CancerCare Teleconference	05/16/2018
Update on the Management of HER2-Positive Disease 28th Annual Mayo Clinic Hematology/Oncology Reviews 2018 Amelia Island, FL	08/04/2018
The Benefits of Clinical Trials for Triple Negative Breast Cancer CancerCare Teleconference	09/26/2018



Breast Cancer Genomics Lakeland Regional Health, Mayo Clinic Care Network Flagstaff, Arizona	10/04/2018
Latest Developments Reported at the 41st San Antonio Breast Cancer Symposium CancerCare Teleconference	12/12/2018
2018 Updates in the Management of HER2-positive Breast Cancer International Oncology Summit 2019 Dubai, United Arab Emirates	01/18/2019
2018 Updates in the Management of Triple-Negative Breast Cancer International Oncology Summit 2019 Dubai, United Arab Emirates	01/18/2019
Breast Cancer Presentation to medical student members of the Cancer Interest Group sponsored by the American Society of Clinical Oncology ASCO Sponsored Cancer Interest Group - Peru	01/25/2019
Immunotherapy Strategies and Novel Drugs in the Horizon for Triple-Negative Breast Cancer AIIMS-Mayo TNBC Symposium New Delhi, India	03/26/2019
Breast Cancer Immunotherapy Clinica Internacional Lima, Peru	10/02/2019
State of the Art of the Treatment of Triple Negative Breast Cancer Clinica Internacional Lima, Peru	10/02/2019
Management of Advanced Triple-Negative Breast Cancer: New Targeted Therapy Options Sociedad Peruana de Cancerologia Paracas, Peru	10/04/2019
Novel Therapeutic Strategies for Metastatic gBRCA-Mutated and Triple-Negative Breast Cancers Mayo Clinic Clinical Multidisciplinary Hematology & Oncology Annual Review Scottsdale, Arizona	02/2020
Immunotherapy Approaches in Early-Stage and Metastatic Breast Cancer International Medical Center Jeddah, Saudi Arabia	02/28/2020
Triple Negative Breast Cancer: Molecular Biology Insights and Novel Therapeutics International Medical Center Jeddah, Saudi Arabia	02/28/2020
New Strategies for the Management of Triple Negative and HER2 Amplified Breast Cancer Department of Oncology, Redsalud Santiago, Chile	08/03/2020
Updates in Triple Negative Breast Cancer Highlights of SABCS 2020 by the Binaytara Foundation	02/21/2021
ADCs for Treating HER2-positive Breast Cancer, Present & Future. Mayo/Huimei Healthcare Joint Breast Conference	03/05/2021
Metastatic Triple Negative Breast Cancer: Strategies to Cope Cancer Care Teleconference	10/06/2021
Immune Checkpoint Inhibitors in the Management of Triple Negative Breast Cancer	02/13/2022

Binaytara Foundation, Virtual Conference

**Oral**

Trainee Council Updates and Sharing 06/03/2018  
 Professional Development and Education Advances  
 2018 ASCO Annual Meeting, Training Program Directors' Breakfast (Training Program Directors and Associate Training Program Directors Only), Education Session  
 Chicago, Illinois

A randomized, double-blind, placebo-controlled trial of oxybutynin (Oxy) for hot flashes (HF): ACCRU study SC-1603 12/07/2018  
 San Antonio Breast Cancer Symposium  
 San Antonio, Texas

Medical Oncology in Breast Cancer Therapy I 05/05/2021  
 11th International Charite Mayo Conference

**Poster**

Response to salvage treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) patients who failed neoadjuvant chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF). 01/2012  
 American Society for Radiation Oncology (ASTRO) Multidisciplinary Head & Neck Cancer Symposium.

Comparison of hepatic artery embolization and selective internal radiation therapy for metastatic neuroendocrine tumors. 01/20/2012  
 2012 Gastrointestinal Cancers Symposium  
 San Francisco, California

A phase I study of vemurafenib and decitabine in metastatic melanoma. 06/2015  
 2015 ASCO Annual Meeting  
 Chicago, Illinois

Utility of PET/CT for surveillance of asymptomatic patients with resected stage III or IV melanoma. 06/2015  
 Received Travel Award for this presentation.  
 American Society of Clinical Oncology (ASCO) National Meeting  
 Chicago, Illinois

Prognostic value of histopathology, stromal tumor infiltrating lymphocytes (sTILs) and adjuvant chemotherapy (AdjCT) in early stage triple negative breast cancer (TNBC). 06/04/2017  
 2017 ASCO Annual Meeting  
 Chicago, Illinois

Prognostic value of histopathology, stromal tumor infiltrating lymphocytes and adjuvant chemotherapy in early stage triple negative breast cancer. 06/30/2017  
 Merit award for this presentation.  
 American Society of Clinic Oncology (ASCO) National Meeting  
 Chicago, Illinois

Prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and its relation to stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC) 12/07/2017  
 San Antonio Breast Cancer Symposium  
 San Antonio, Texas

Tumor-infiltrating lymphocytes (TILs) in androgen receptor (AR)-positive, triple-negative breast cancer (TNBC) 01/25/2018  
 American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Immuno-Oncology Symposium  
 San Francisco, California

Treatment of neoplastic fever and sweats in two cancer patients with oxybutynin. 2019 Supportive Care in Oncology Symposium	10/26/2019
Liquid biopsy of the immune environment: Evaluation of peripheral blood mononuclear cells (PBMCs) with CyTOF and response to trastuzumab (T)-based neoadjuvant chemotherapy (NAC) in HER2+ breast cancer (BC). 2020 ASCO Virtual Scientific Program, Breast Cancer—Local/Regional/Adjuvant	05/29/2020 - 05/31/2020
Digital spatial profiling of immune-related proteins in luminal androgen receptor (LAR) vs non-LAR triple-negative breast cancer (TNBC). 2021 San Antonio Breast Cancer Symposium, Virtual Presentation	12/2021
Long-term outcomes of patients with node-negative (N0), triple-negative breast cancer (TNBC) who did not receive adjuvant chemotherapy according to stromal TILs (sTILs). 2021 ASCO Annual Meeting	06/04/2021
<b>Regional</b>	
<b>Invited</b>	
A bleeding disorder with normal coagulation tests. Clotter's Rounds, Mayo Clinic Rochester, MN	11/2014
Evaluation and management of Gestational Trophoblastic Disease. Oncology Fellows Conference Rochester, MN	12/2014
Extracorporeal Photopheresis for Graft-vs-Host Disease. Transfusion Medicine Conference, Mayo Clinic Rochester, MN	01/2015
The Critically Ill Cancer Patient. Oncology Morbidity and Mortality Conference, Mayo Clinic Rochester, MN	03/2015
HHV-6 infection and Posterior Reversible Encephalopathy Syndrome in an allogeneic stem cell transplant recipient. Combined Hematology and Infectious Diseases Conference, Mayo Clinic Rochester, MN	08/2015
Second primary malignancies in patients with head and neck and lung cancer. Oncology Morbidity and Mortality Conference, Mayo Clinic Rochester, MN	12/2015
A case of impending visceral crisis in a patient with metastatic breast cancer Oncology Fellows Conference, Mayo Clinic Rochester, MN	04/01/2016
Breast Cancer Primer Oncology Fellows Conference Rochester, MN	07/22/2016
Triple Negative Breast Cancer: Starting from Scratch Oncology CME Conference, Mayo Clinic Rochester, MN	09/2016
Triple Negative Breast Cancer: Starting from Scratch Breast Imaging and Intervention In-Service Conference, Mayo Clinic Rochester, MN	03/22/2017
New Clinical Approaches to Triple-Negative Breast Cancer Multidisciplinary Breast Cancer Conference Mayo Clinic; Rochester, Minnesota	01/19/2018

Healthcare in Ecuador Rochester Community and Technical College Rochester, Minnesota	04/11/2018
Breast Cancer Internal Medicine Residency Noon Conference 2018	07/12/2018
Triple-Negative Breast Cancer: New Insights into the Biology and Emerging Drug Therapies OncLive State of the Science Summit Minneapolis, MN, Minnesota	11/14/2018
The Mayo Triple-Negative Breast Cancer Cohort Multidisciplinary Breast Cancer Conference Rochester, Minnesota	04/13/2018
Immunotherapy for Breast Cancer and PD-L1 Testing Multidisciplinary Breast Cancer Conference, Mayo Clinic Rochester, Minnesota	02/14/2020
Updates in Breast Cancer Mayo Clinic Oncology Review Rochester, Minnesota	07/18/2020
Triple Negative Breast Cancer: It's Time to Focus on the Positives! Cancer Center Grand Rounds, Gundersen Health System	09/08/2020
Metastatic Triple Negative Breast Cancer Medical Oncology Fellowship Core Curriculum Mayo Clinic, Rochester, MN	03/10/2021
Updates in Breast Cancer Mayo Clinic Oncology Review Rochester, Minnesota	07/06/2021
Towards a Liquid Biopsy of the Immune Tumor Microenvironment Breast Cancer Care Innovation, Disruptive Technologies and Early Adopters Rochester, Minnesota	09/17/2021
Breast Cancer Updates: Focus on Triple Negative Breast Cancer Mayo Clinic, MN	10/05/2021
Systemic Therapy for Triple Negative Breast Cancer Radiation Oncology Residency Program, Mayo Clinic, MN	11/09/2021
Breast Cancer Updates: Focus on HER2+ Breast Cancer Mayo Clinic, MN	03/15/2022
<b>Oral</b>	
A B-wildering Case of Paraplegia Awarded the 1st place among 27 clinical vignette presentations American College of Physicians (ACP) Clinical Vignette Competition, Iowa Chapter Iowa	02/2012
"Pretty in Pink": Hypereosinophilic syndrome. Internal Medicine Grand Rounds, University of Iowa Hospitals and Clinics	05/2014
Best of ASCO, Hematology Updates Hematology Clinical CME Conference, Mayo Clinic Rochester, MN	07/20/2016
2019 Breast Cancer Updates: Focus on Triple-Negative Breast Cancer and Metastatic HER2-Positive Breast Cancer Oncology CME Conference, Mayo Clinic Rochester, Minnesota	09/03/2019

Updates from the 2020 Virtual San Antonio breast Cancer Symposium  
Multidisciplinary Breast Cancer Conference,  
Mayo Clinic, Rochester, MN

12/18/2020

## Research Grants Awarded

### Active Grants

#### Federal

KL2 Scholar Institutional Career Development Core (CCaTS KL2). Funded by National Center for Advancing Translational Sciences. (KL2 TR 02379) 09/2017 - 06/2022

#### Industry

Program Amend 1- IMMU-132-05: Phase III Study of Sacituzumab Govitecan in Relapsed/Refractory Triple-Negative Breast Cancer. Funded by Director / Immunomedics. (IMMU-132-05) 04/2018 - 04/2020  
Principal Investigator

Program CBYL719H12301: Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced TNBC. Funded by Novartis. (CBYL719H12301) 10/2020 - 10/2023  
Director / Principal Investigator

Program MCR (Lead) GS-US-586-6144, A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic TNBC. Funded by Gilead Sciences. (GS-US-586-6144) 01/2021 – 01/2023  
Director / Principal Investigator

Program MCR\_AL-TNBC-01: TENACITY: A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer. Funded by Ayala. (AL-TNBC-01) 02/2021 - 01/2023  
Director / Principal Investigator

Program TBCRC056: A phase II study of niraparib with dostarlimab therapy as neoadjuvant treatment for patients with BRCA-mutated breast cancer. Funded by Dana Farber/Harvard Cancer Institute. (TBCRC056) 03/2022 – 02/2024  
Director / Principal Investigator

#### Mayo Clinic

Program Targeting DNA methyltransferases in metastatic DNMT3A(+) triple negative breast cancer. Funded by the Mayo Clinic Research Pipeline K2R Award. 01/2021 - 12/2021  
Director / Principal Investigator

Program S2007 A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases. Funded by Hybrid Intramural Proposal for Cancer Center 12/2021 – 11/2025  
Director / Principal Investigator

### Completed Grants

#### Mayo Clinic

Program Development of a Multiplexed Proteomics Panel for the Identification of Tissue of Origin in Patients with Cancer of Unknown Primary. Funded by Director / CCaTS Office of Translation to Practice – Advance the Practice Research Award 01/2021 – 12/2021  
Principal Investigator

Co-Program Utility of PET/CT for routine surveillance of asymptomatic patients with resected stage III or IV melanoma. Funded by SGP - Small Grants Program <\$10K 07/2015 - 07/2017  
Director / Principal Investigator

## Bibliography

### Peer-reviewed Articles

1. Cherrez Ojeda I, Cruz E, **Leon Ferre R**, Mantilla R, Guerrero T, Soria J, Tafur A, Chica L, Gabino G. Chronic autoimmune urticaria in children. *Allergol Immunopathol (Madr)*. 2009 Jan-Feb; 37: (1)43-7. PMID: 19268061
2. **Leon-Ferre RA**, Abu Hejleh TB, Halfdanarson TR. Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature. *Clin Adv Hematol Oncol*. 2012 Aug; 10(8):546-8. PMID: 23073056
3. **Leon-Ferre RA**, Weiler CR, Halfdanarson TR. Hypereosinophilic syndrome presenting as an unusual triad of eosinophilia, severe thrombocytopenia, and diffuse arterial thromboses, with good response to mepolizumab. *Clin Adv Hematol Oncol*. 2013 May; 11(5):317-9. PMID: 23880717
4. **Leon-Ferre RA**, Koch B, Rosenstein LJ. A B-wildering case of paraplegia: cobalamin deficiency. *Am J Med*. 2013 Dec; 126: (12)1045-7. PMID: 24083644 DOI: 10.1016/j.amjmed.2013.08.005
5. Engelman ES, **Leon-Ferre R**, Naraev BG, Sharma N, Sun S, O'Dorisio TM, Howe J, Button A, Zamba G, Halfdanarson TR. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. *Pancreas*. 2014 Mar; 43 (2):219-25 PMID: 24518499 PMCID: 4307836 DOI: 10.1097/MPA.0000000000000030
6. Xia C, **Leon-Ferre R**, Laux D, Deutsch J, Smith BJ, Frees M, Milhem M. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). *Cancer Chemother Pharmacol*. 2014 Oct; 74: (4)691-7. PMID: 25062770 PMCID: 4175037 DOI: 10.1007/s00280-014-2501-1
7. **Leon-Ferre RA**, Markovic SN. Nab-paclitaxel in patients with metastatic melanoma. *Expert Rev Anticancer Ther*. 2015; 15: (12)1371-7. PMID: 26536477 DOI: 10.1586/14737140.2015.1110024
8. **Leon-Ferre RA**, Majithia N, Loprinzi CL. Management of hot flashes in women with breast cancer receiving ovarian function suppression. *Cancer Treat Rev*. 2017 Jan; 52: 82-90. PMID: 27960127 DOI: 10.1016/j.ctrv.2016.11.012
9. **Leon-Ferre RA**, Kottschade LA, Block MS, McWilliams RR, Dronca RS, Creagan ET, Allred JB, Lowe VJ, Markovic SN. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. *Melanoma Res*. 2017 Aug; 27 (4):335-341 PMID: 28296712 DOI: 10.1097/CMR.0000000000000344
10. McBane RD, McBane li R, Loprinzi CL, Ashrani A, Perez-Botero J, **Leon Ferre RA**, Henkin S, Lenz CJ, Le-Rademacher JG, Wysokinski WE. Apixaban and dalteparin in active malignancy associated venous thromboembolism. *The ADAM VTE Trial*. *Thromb Haemost*. 2017 Oct 5; 117 (10):1952-1961 Epub 2017 Aug 24 PMID: 28837207 DOI: 10.1160/TH17-03-0193
11. Ravi P, **Leon-Ferre R**, Thompson CA. 47-Year-Old Woman with Anemia and Thrombocytopenia. *Mayo Clin Proc*. 2018 Jan; 93 (1):108-112 Epub 2017 Nov 13 PMID: 29141773 DOI: 10.1016/j.mayocp.2017.02.024
12. **Leon-Ferre RA**, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Visscher DW, Goetz MP. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. *Breast Cancer Res Treat*. 2018 Jan; 167 (1):89-99 Epub 2017 Sept 14 PMID: 28913760 PMCID: 5790598 DOI: 10.1007/s10549-017-4499-7
13. Duma N, Gast KC, Choong GM, **Leon-Ferre RA**, O'Sullivan CC. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer? *Curr Oncol Rep*. 2018 Jun 8; 20 (8):63 Epub 2018 June 08 PMID: 29884921 DOI: 10.1007/s11912-018-0709-7
14. **Leon-Ferre RA**, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, Hawse JR, Boughey JC, Ruddy KJ. A contemporary review of male breast cancer: current evidence and unanswered questions. *Cancer Metastasis Rev*. 2018 Dec; 37 (4):599-614 PMID: 30232577 DOI: 10.1007/s10555-018-9761-x
15. Hudecek J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM, **International Immuno-Oncology Biomarker Working Group**. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. *NPJ Breast Cancer*. 2020; 6:15 Epub 2020 May 12 PMID: 32436923 PMCID: 7217941 DOI: 10.1038/s41523-020-0155-1
16. Norton N, Youssef B, Hillman DW, Nassar A, Geiger XJ, Necela BM, Liu H, Ruddy KJ, Polley MC, Ingle JN, Couch FJ, Perez EA, Liu MC, Carter JM, **Leon-Ferre RA**, Boughey JC, Somers EB, Kalari KR, Visscher DW, Goetz MP, Knutson KL. Folate receptor alpha expression associates with improved disease-free survival in

triple negative breast cancer patients. NPJ Breast Cancer. 2020; 6:4 Epub 2020 Feb 04 PMID: 32047850 PMCID: 7000381 DOI: 10.1038/s41523-020-0147-1

17. Yadav S, Karam D, Bin Riaz I, Xie H, Durani U, Duma N, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Couch FJ, **Leon-Ferre RA**, Ruddy KJ. Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer. 2020 Jan 1; 126 (1):26-36 Epub 2019 Oct 07 PMID: 31588557 PMCID: 7668385 DOI: 10.1002/cncr.32472
18. Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudecek J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, Andre F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monso MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R, **International Immuno-Oncology Biomarker Working Group**. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020; 6:17 Epub 2020 May 12 PMID: 32411819 PMCID: 7217863 DOI: 10.1038/s41523-020-0156-0
19. Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudecek J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD, **International Immuno-Oncology Biomarker Working Group**. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2020; 6:16 Epub 2020 May 12 PMID: 32411818 PMCID: 7217824 DOI: 10.1038/s41523-020-0154-2
20. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, **Leon Ferre RA**, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020 Feb; 18 (2):411-421 Epub 2019 Nov 28 PMID: 31630479 DOI: 10.1111/jth.14662
21. **Leon-Ferre RA**, Novotny PJ, Wolfe EG, Faubion SS, Ruddy KJ, Flora D, Dakhil CSR, Rowland KM, Graham ML, Le-Lindqwister N, Smith TJ, Loprinzi CL. Oxybutynin vs Placebo for Hot Flashes in Women with or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI Cancer Spectr. 2020 Feb; 4 (1):pkz088 Epub 2019 Oct 21 PMID: 32337497 PMCID: 7050158 DOI: 10.1093/jncics/pkz088
22. Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, **Leon-Ferre R**, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M, International Immuno-Oncology Biomarker Working Group. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020 Apr; 250 (5):667-684 Epub 2020 Apr 09 PMID: 32129476 DOI: 10.1002/path.5406
23. **Leon-Ferre RA**, Perez EA, Hillman DW, Bueno C, Perez AT, Chen B, Jenkins RB, Northfelt DW, Johnson DB, Carolla RL, Zon RT, Moreno-Aspitia A. N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. Breast Cancer Res Treat. 2020 Aug; 182 (3):613-622 Epub 2020 June 05 PMID: 32504284 PMCID: 7535136 DOI: 10.1007/s10549-020-05709-z
24. \* Anampa-Guzman A, Brito-Hijar AD, Gutierrez-Narvaez CA, Molina-Ruiz AR, Simo-Mendoza V, Gonzalez-Woge M, de la O Murillo A, **Leon-Ferre R**. American Society of Clinical Oncology-Sponsored Oncology Student Interest Groups in Latin America. JCO Glob Oncol. 2020 Sep; 6:1439-1445 PMID: 32997539 PMCID: 7531611 DOI: 10.1200/GO.20.00363

25. Cathcart-Rake E, Novotny P, **Leon-Ferre R**, Le-Rademacher J, Storrack EM, Adjei AA, Terstriep S, Glaser R, Giuliano A, Mitchell WR, Page S, Austin C, Deming RL, Ferreira MA, Lafky JM, Birrell SN, Loprinzi CL. A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. *Support Care Cancer*. 2021 Jan; 29 (1):387-396 Epub 2020 May 06 PMID: 32372176 PMCID: 7644633 DOI: 10.1007/s00520-020-05473-2
26. Polley MC, **Leon-Ferre RA**, Leung S, Cheng A, Gao D, Sinnwell J, Liu H, Hillman DW, Eyman-Casey A, Gilbert JA, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari K, Couch F, Carter JM, Visscher DW, Nielsen TO, Goetz MP. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. *Breast Cancer Res Treat*. 2021 Feb; 185 (3):557-566 Epub 2021 Jan 03 PMID: 33389409 PMCID: 7925385 DOI: 10.1007/s10549-020-06030-5
27. **Leon-Ferre RA**, Hieken TJ, Boughey JC. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. *Ann Surg Oncol*. 2021 Apr; 28 (4):2111-2119 Epub 2021 Jan 23 PMID: 33486641 DOI: 10.1245/s10434-020-09480-9
28. Carter JM, Polley MC, **Leon-Ferre RA**, Sinnwell J, Thompson KJ, Wang X, Ma Y, Zahrieh D, Kachergus JM, Solanki M, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Thompson EA, Goetz MP. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. *Clin Cancer Res*. 2021 Jun 09. [Epub ahead of print] PMID: 34108182 DOI: 10.1158/1078-0432.CCR-21-0343
29. \* Yadav S, Giridhar KV, Leone JP, **Leon-Ferre RA**, Ruddy KJ. A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer *Breast Cancer Management*. 2021; 10(3). DOI: <https://doi.org/10.2217/bmt-2021-0001>
30. \* Anampa-Guzmán A, Loli-Guevara S, Gutierrez-Narvaez CA, Nimboma LE, Leon-Ferre R. ASCO-Sponsored Oncology Student Interest Groups in the World. *JCO Glob Oncol*. 2021 Sep;7:1586-1592. doi: 10.1200/GO.21.00353. PMID: 34843374; PMCID: PMC8624020.
31. Aspros KGM, Carter JM, Hoskin TL, Suman VJ, Subramaniam M, Emch MJ, Ye Z, Sun Z, Sinnwell JP, Thompson KJ, Tang X, Rodman EPB, Wang X, Nelson AW, Chernukhin I, Hamdan FH, Bruinsma ES, Carroll JS, Fernandez-Zapico ME, Johnsen SA, Kalari KR, Huang H, **Leon-Ferre RA**, Couch FJ, Ingle JN, Goetz MP, Hawse JR. Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer. *npj Breast Cancer* 8, 20 (2022). <https://doi.org/10.1038/s41523-022-00387-0>
32. O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, **Leon-Ferre R**, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. *Breast Cancer Res Treat*. 2022 May 11. doi: 10.1007/s10549-022-06602-7. Epub ahead of print. PMID: 35545724.
33. Thompson K, **Leon-Ferre RA**, Sinnwell J, Zahrieh D, Suman V, Metzger Filho O, Asad S, Stover D, Carey L, Sikov W, Ingle J, Liu M, Carter J, Klee E, Weinshilboum R, Boughey J, Wang L, Couch FJ, Goetz M, Kalari K. Luminal Androgen Receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. *NAR Cancer*. 2022 May 19.

### Non-Peer-reviewed Articles

1. **Leon Ferre RA**. Thriving at Your First ASCO Annual Meeting ASCO Connection. 2018.

### Book Chapters

1. **Leon-Ferre R**, Arean-Cuns C, Zambrano-Tola E. Aspectos genéticos y moleculares de tumores óseos y de partes blandas [Cytogenetic and Molecular aspects of Bone and Soft Tissue Neoplasms]. In: E Blasco-Olaetxea, J Garcia-Tamayo. *Avances en Patología: Patología del Cáncer [Advances in Pathology: Pathology of Cancer]*.5th ed. Cabildo de Fuerteventura, Spain:2009.
2. **Leon-Ferre R**, Arean-Cuns C, Zambrano-Tola E.. Síndromes hereditarios asociados con sarcomas [Hereditary Syndromes Associated with Sarcomas]. In: E Blasco-Olaetxea, J Garcia-Tamayo. *Avances en Patología: Patología del Cáncer [Advances in Pathology: Pathology of Cancer]*.5th ed. Cabildo de Fuerteventura, Spain:2009.
3. **Leon-Ferre R**, Zambrano E. Pediatric Bone Tumors. In: AC Mackinnon Jr. *Pediatric Neoplasia: Advances in Molecular Pathology and Translational Medicine*. Chicago, IL: Humana Press;2012.141-167p.
4. \* Yadav S, Giridhar KV, Ruddy KJ, **Leon-Ferre RA**. Common Issues in Breast Cancer Survivors. In: Kimmick G.G., Shelby R.A., Sutton L.A., editor(s). *Common considerations in male breast cancer survivors*. Cham: Springer International Publishing; 2021. p. 319-328.

### Editorials



1. **Leon-Ferre RA**, Stover DG. Supporting the Future of the Oncology Workforce: ASCO Medical Student and Trainee Initiatives. *J Oncol Pract* 2018 May; 14 (5):277-280 Epub 2018 Apr 20
2. Yadav S, Giridhar KV, Taraba J, **Leon-Ferre R**, Ruddy KJ. Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences? *Expert Opin Drug Saf* 2020 Aug; 19 (8):923-926 Epub 2020 July 27
3. **Leon-Ferre R**, Ruddy KJ, Staff NP, Loprinzi CL. Fit for Chemo: Nerves May Thank You. *J Natl Cancer Inst* 2017 Feb; 109 (2) Epub 2016 Oct 28 PMID:27794125 DOI:10.1093/jnci/djw208

## Commentaries

## Abstracts

1. Mantilla RD, Tafur A, Soria J, Cruz E, Cherrez IM, **Leon Ferre R**, Guerrero TA, Chica LJ. Awareness of Obstructive Sleep Apnea in a Latin American Community American Journal of Respiratory and Critical Care Medicine.2009 May 17;179: Abstract no.A2147.
2. Engelman E, **Leon-Ferre R**, Naraev B, Sharma N, Sun S, O'Dorisio T, Halfdanarson T. Comparison of Hepatic Artery Embolization and Hepatic Radioembolization for Metastatic Neuroendocrine Tumors *Journal of Clinical Oncology*.2012 May 20;
3. Engelman ES, **Leon-Ferre R**, Naraev BG, Sharma N, Button AM, Zamba G, Sun S, O'Dorisio TM, Halfdanarson TR. Clinical outcomes and predictive value of chromogranin A (CgA) and pancreastatin (PcSt) in liver-directed therapies (LDTs) for well-differentiated metastatic neuroendocrine tumors. *J Clin Oncol*.2012 June 01.
4. Phadke S, Engelman E, **Leon-Ferre R**, Abushahin L, Mott S, Zakharia Y, Milhem M. A Phase I Study Evaluating Safety and Efficacy of Vemurafenib in Combination with Decitabine in Metastatic Melanoma *Journal of Clinical Oncology*.5/2015;9056. Abstract no.9056.
5. **Leon-Ferre RA**, Kottschade LA, Lowe VJ, Markovic S. Utility of pet/ct for surveillance of asymptomatic patients with resected stage iii or iv melanoma. *J Clin Oncol*. 2015 May 20; 33(15).
6. **Leon-Ferre RA**, Polley M, Liu H, Gilbert J, Cafourek V, Hillman D, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu M, Ingle JN, Kalari K, Couch FJ, Visscher DW, Goetz MP. Prognostic Value of Histopathology, Stromal Tumor Infiltrating Lymphocytes and Adjuvant Chemotherapy in Early Stage Triple Negative Breast Cancer *Journal of Clinical Oncology*.5/2017; Abstract no.533.
7. Polley M-Y, **Leon-Ferre RA**, Liu H, Gilbert J, Cafourek V, Hillman DW, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari K, Couch F, Visscher DW, Goetz MP. Mayo clinic TNBC outcome calculator: A clinical calculator to predict disease relapse and survival in women with triple-negative breast cancer San Antonio Breast Cancer Symposium.2017; Abstract no.P1-06-07.
8. **Leon-Ferre RA**, Polley M-Y, Liu H, Gilbert J, Cafourek V, Hillman D, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari K, Couch FJ, Visscher DW, Goetz MP. Prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and its relation to stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC) San Antonio Breast Cancer Symposium.2017;
9. **Leon-Ferre RA**, Polley MY, Liu H, Cafourek V, Boughey JC, Kalari KR, Negron V, Liu MC, Ingle JN, Couch FJ, Visscher DW, Goetz MP. Tumor-infiltrating lymphocytes in androgen receptor-positive, triple-negative breast cancer *J Clin Oncol*. 2018; 36(suppl 5S). Abstract no. 5.
10. Ghosh T, Goetz MP, **Leon Ferre RA**, Liu H, Polley M-Y, Ingle J, Cafourek V, Hillman D, Carter J, Visscher D. Prognostic Assessment of Stromal and Non-Stromal Tumor-Infiltrating Lymphocytes (TILs) in Triple-Negative Breast Cancer (TNBC) USCAP Annual Meeting. 2018.
11. \* Andrade Gonzalez XA, Fuentes Bayne HE, Mann H, Mendez Hernandez A, Tafur AJ, **Leon-Ferre RA**. Current trends and inpatient outcomes of venous thromboembolism-related admissions among patients with diffuse large B-cell lymphoma: A Nationwide Inpatient Sample Database analysis. *Journal of Clinical Oncology*. 2018; 36(15\_suppl):e19546-e19546.
12. \* Andrade Gonzalez XA, Fuentes HE, Mendez A, Mann H, Tafur AJ, **Leon-Ferre RA**. Current trends and inpatient outcomes of venous thromboembolism-related admissions in patients with Philadelphia-negative myeloproliferative neoplasms: A Nationwide Inpatient Sample Database analysis. *Journal of Clinical Oncology*. 2018; 36(16\_suppl):e19030-e19030.
13. McBane RD, Wysokinski WE, Le-Rademacher JG, Ashrani A, Tafur AJ, Gundabolu K, Perez-Botero J, Perepu U, Anderson DM, Kuzma C, **Leon Ferre RA**, Henkin S, Lenz CJ, Loprinzi CL. Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial American Society of Hematology. 2018; Abstract no. 421.

14. **Leon-Ferre RA**, Le-Rademacher J, Terstriep S, Glaser R, Novotny, Giuliano A, Copur MS, Jones C, Page S, Mitchell W, Birrell SN, Loprinzi CL. A randomized, double-blind, placebo-controlled trial of testosterone (T) for aromatase inhibitor-induced arthralgias (AIA) in postmenopausal women: Alliance A221102 San Antonio Breast Cancer Symposium. 2018.
15. **Leon-Ferre RA**, Polley, Liu H, Kalari KR, Boughey JC, Liu MC, Cafourek V, Negron V, Ingle JN, Thompson KJ, Tang X, Barman P, Carlson E, Visscher DW, Carter JM, Couch FJ, Goetz MP. Characteristics, outcomes and prognostic factors of luminal androgen receptor (LAR) triple-negative breast cancer (TNBC) San Antonio Breast Cancer Symposium. 2018; Abstract no. P3-08-01.
16. Boughey JC, Hoskin TL, Cocco D, Day CN, **Leon-Ferre R**, Habermann EB, Goetz MP. The 21-gene recurrence score and chemotherapy use in triple negative breast cancer (TNBC) and HER2 positive breast cancer: A National Cancer Database study San Antonio Breast Cancer Symposium. 2018; Abstract no. P3-08-09.
17. **Leon-Ferre RA**, Novotny PJ, Faubion SS, Ruddy KJ, Flora D, Dakhil C, Rowland KM, Graham ML, Le-Lindqwister N, Loprinzi CL. A randomized, double-blind, placebo-controlled trial of oxybutynin (Oxy) for hot flashes (HF): ACCRU study SC-1603 San Antonio Breast Cancer Symposium. 2018; Abstract no. GS6-02.
18. Yadav S, **Leon-Ferre RA**, Jimenez RE, Hawse JR, Hieken TJ, Couch FJ, Boughey JC, Ruddy KJ. Clinical characteristics and survival of patients with male breast cancer: The Mayo Clinic experience San Antonio Breast Cancer Symposium. 2018; Abstract no. P6-19-05.
19. Giridhar KV, Choong GM, **Leon-Ferre RA**, O'Sullivan CC, Ruddy KJ, Haddad TC, Hobday TJ, Peethambaram PP, Moynihan TJ, Loprinzi CL, Liu MC, Suman VJ, Goetz MP. Clinical management of metastatic breast cancer (MBC) after CDK 4/6 inhibitors: A retrospective single-institution study San Antonio Breast Cancer Symposium. 2018; Abstract no. P6-18-09.
20. Riaz Sipra QU, Bin Riaz I, Husnain M, Raina A, Khan A, Akhtar M, Wang Z, Murad H, **Leon-Ferre RA**. Short versus long duration of adjuvant trastuzumab (T) in HER2+ breast cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs) Journal of Clinical Oncology. 2019; 37(no.15\_suppl).
21. Smith TJ, Yarchoan M, **Leon-Ferre RA**, Tucker W, Loprinzi CL. Treatment of neoplastic fever and sweats in two cancer patients with oxybutynin Journal of Clinical Oncology. 2019 Nov 1; 37(31):128
22. Villasboas JC, McGrath K, Amir EA, **Leon-Ferre RA**, Goetz MP, Boughey JC, Carter JM, Kalari KR, Wang L, Suman VJ, Weinshilboum R, Ansell SM. High dimensional immune monitoring of peripheral blood samples from breast cancer patients using mass cytometry (CyTOF) Journal for ImmunoTherapy of Cancer. 11/08/2019; 7(282):272. Abstract no. P23.
23. O'Sullivan CC, Kalari KR, Suman VJ, Vedell PT, Moyer A, Carlson E, Sinnwell J, Alaparthi T, Tang X, Thompson K, Sung J, Moreno-Aspitia A, Northfelt D, Liu MC, Haddad TC, Peethambaram P, Chumsri S, Ruddy KJ, Giridhar KV, **Leon-Ferre RA**, Gill P, Ranginwala M, Javed A, Batoo S, McMenomy BP, Weinshilboum R, Wang L, Goetz MP. Comprehensive tumor sequencing to identify biomarkers of palbociclib response: first report of the PROMISE study. San Antonio Breast Cancer Symposium 2019. 2019; Abstract no. P2-11-07.
24. Yadav Siddhartha, Sangaralingham Lindsey, Payne Stephanie, Hieken Tina, Boughey Judy, Mutter Robert, Hawse John, Jimenez Rafael, Freedman Rachel, Choudhery S, Couch Fergus, Vachon Celine, Shah Nilay, **Leon Ferre Roberto**, Ruddy Kathryn, Giridhar Karthik. Surveillance Mammography After Treatment for Male Breast Cancer San Antonio Breast Cancer Symposium. San Antonio, TX. 2019 December.
25. **Leon-Ferre RA**, McGrath K, Carter JM, Kalari KR, Suman VJ, Weinshilboum R, Wang L, Knutson KL, Anse SM, Boughey JC, Villasboas JC, Goetz MP. Deep phenotyping using cytof identifies peripheral blood immune signatures associated with clinical outcomes and molecular subtypes in patients with early-stage triple negative breast cancer (tnbc) Cancer Research. 2020 Feb; 80(4):P5-04-09
26. Giridhar KV, Choong GM, Yadav S, Polley EC, **Leon-Ferre RA**, Liu MC, Goetz MP, Couch FJ. Distribution of the 21-gene recurrence score (rs) assay (oncotype dx) in carriers of germline mutations associated with breast cancer predisposition syndromes Cancer Research. 2020 Feb; 80(4):P5-03-07
27. Choong GMY, **Leon-Ferre RA**, O'Sullivan CC, Ruddy KJ, Haddad TC, Hobday TJ, Peethambaram PP, Loprinzi CL, Liu MC, Suman VJ, Goetz MP, Giridhar KV. Evaluation of mean corpuscular volume (mcv) as a pharmacodynamic predictive biomarker in patients receiving cdk4/6 inhibitors for metastatic breast cancer (mbc) Cancer Research. 2020 Feb; 80(4):P1-19-42
28. Carter JM, Polley MYC, Sinnwell JP, **Leon-Ferre RA**, Couch FJ, Kalari KR, Boughey JC, Liu MC, Visscher DW, Goetz MP. Y frequency, characteristics and prognostic factors of pd-l1+triple negative breast cancer using the pd-l1 sp142 companion assay Cancer Research. 2020 Feb; 80(4):PD1-08

29. **Leon-Ferre RA**, McGrath K, Suman VJ, Carter JM, Kalari KR, Weinshilboum RM, Wang LW, Ingle JN, Knutson KL, Ansell SM, Boughey JC, Villasboas JC, Goetz MP. Liquid biopsy of the immune environment: evaluation of peripheral blood mononuclear cells (pbmcs) with cytof and response to trastuzumab (t)-based neoadjuvant chemotherapy (nac) in her2+breast cancer (bc) *Journal Of Clinical Oncology*. 2020 May 20; 38(15 Suppl):592. Epub 1900 Jan 01.
30. Chumsri S, Carter JM, Ma YH, Hinerfeld D, Brauer HA, Warren S, Nielsen TO, Asleh K, Joensuu H, Perez EA, **Leon-Ferre RA**, Hillman DW, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch F, Knutson KL, Goetz MP, Thompson EA. Role of intratumoral nk cells in triple-negative breast cancer in the finxx trial and mayo clinic cohort *Journal Of Clinical Oncology*. 2020 May 20; 38(15 Suppl):510. Epub 1900 Jan 01.
31. Liu MC, Giridhar KV, **Leon Ferre RA**, Carroll JL, Goetz MP, Haddad TC, Smith DR, Yadav S, Kapoor V, Liu G, George T, Ericson N, Ramirez AB, Kaldjian E, Haselkorn KE; Abstract 3119: Comparison of circulating tumor cell (CTC) derived DNA and circulating cell-free DNA (cfDNA) from simultaneous blood sampling of patients with metastatic breast cancer (MBC). *Cancer Res* 15 August 2020; 80 (16\_Supplement): 3119. <https://doi.org/10.1158/1538-7445.AM2020-3119>
32. Chumsri S, Carter JM, Ma Y, Hinerfeld D, Brauer HA, Warren S, Nielsen TO, Asleh K, Joensuu H, Perez EA, **Leon Ferre RA**, Hillman DW, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Knutson KL, Goetz MP, Thompson EA. Spatially defined immune-related proteins and outcome in triple negative breast cancer in the FinXX trial and Mayo Clinic cohort *Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium*; 2020 Dec 8-11. 2020; 81(4 Suppl). Abstract no. PS6-02. Epub 2021 Feb 01.
33. Haddad TC, D'Assoro AB, Suman VJ, Carter JM, McMenomy BP, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs C, Oh SY, Clark A, Mayer IA, Keyomarsi K, **Leon-Ferre RA**, Giridhar KV, O'Sullivan C, Peethambaram PP, Hobday TJ, Liu MC, Ingle JN, Goetz MP. Abstract PD2-05: Randomized phase II trial to evaluate alisertib alone or combined with fulvestrant for advanced, endocrine-resistant breast cancer (TBCRC 041) *Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium*. 2021; 81(4 Suppl). Abstract no. PD2-05.
34. Carter JM, Chumsri S, Hillman DW, Zahrieh DM, Ma Y, Wang X, Kachergus JM, Boughey JC, Liu MC, Kalari KR, Villasboas JC, **Leon Ferre RA**, Couch FJ, Goetz MP, Thompson EA. Abstract PS16-01: Intra-epithelial tumor immune landscapes are associated with clinical outcomes in early-stage triple-negative breast cancer *Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium*. 2021; 81(4 Suppl). Abstract no. PS16-01.
35. O'Sullivan CC, Kalari KR, Suman VJ, Vedell PT, Moyer A, Eyman Casey AD, Sinnwell J, Tang X, Thompson K, Moreno-Aspitia A, Northfelt DW, Liu MC, Haddad TC, Chumsri S, Peethambaram P, Ruddy KJ, Giridhar KV, **Leon-Ferre RA**, Nordmark A, Bergqvist M, McMenomy BP, Weinshilboum RM, Wang L, Goetz MP. Abstract PS5-24: Novel genomic variants and pathways associated with baseline serum thymidine kinase 1 levels in HR-positive HER2-negative MBC patients commencing palbociclib and letrozole. *Cancer Research* 2021; 81: PS5-24-PS25-24.
36. **Leon-Ferre RA**, Carter JM, Hillman DW, Tenner KS, Zahrieh D, Liu MC, Ingle JN, Kalari KR, Visscher DW, Boughey JC, Couch F. Long-term outcomes of patients with node-negative (N0), triple-negative breast cancer (TNBC) who did not receive adjuvant chemotherapy according to stromal TILs (sTILs). DOI: 10.1200/JCO.2021.39.15\_suppl.548 *Journal of Clinical Oncology* 39, no. 15\_suppl (May 20, 2021) 548-548..
37. O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Diab S, Punie K, Sardesai S, Hamilton E, Loirat D, Traina TA, **Leon-Ferre R**, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Hong Q, Phan S, Cortés J, 258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC). *Annals of Oncology* 2021; 32: S473-S474.
38. O'Sullivan CC, He J, Suman VJ, Kalari KR, **Leon-Ferre RA**, Villasboas-Bisneto JC, Chalasani P, Gokalp Yasar D, Anderson DM, Stella PJ, Jaslowski AJ, Tannenbaum SH, Saverimuthu A, Northfelt D, Moreno-Aspitia A, Carter JM, Liu MC, Wang L, Lou Z, Goetz MP; Abstract OT2-19-05: A phase I/II trial of abemaciclib and T-DM1 in women and men with HER2-positive advanced or metastatic breast cancer that has progressed on treatment with a taxane, trastuzumab and pertuzumab (THP) (ACCRU-BR-1801). *Cancer Res* 15 February 2022; 82 (4\_Supplement): OT2-19-05. <https://doi.org/10.1158/1538-7445.SABCS21-OT2-19-05>
39. **Leon-Ferre RA**, Carter JM, Zahrieh DM, Hillman DW, Chumsri S, Ma Y, Kachergus JM, Wang X, Boughey JC, Liu MC, Ingle JN, Kalari KR, Villasboas Bisneto JC, Couch FJ, Aubrey Thompson E, Goetz MP; Abstract P1-04-01: Digital spatial profiling of immune-related proteins in luminal androgen receptor (LAR) vs non-LAR triple-negative breast cancer (TNBC). *Cancer Res* 15 February 2022; 82 (4\_Supplement): P1-04-01. <https://doi.org/10.1158/1538-7445.SABCS21-P1-04-01>

40. O'Sullivan CC, He J, Sinnwell J, Suman VJ, Kalari KR, Vedell PT, Moyer AM, Tang X, Thompson KJ, Casey AE, Moreno-Aspitia A, Northfelt DW, Liu MC, Haddad TC, Chumsri S, McMenemy B, Peethambaram P, Ruddy KJ, Giridhar KV, **Leon-Ferre RA**, Bergqvist M, Nordmark A, Weinshilboum RM, Wang L, Goetz MP; Abstract P5-13-22: Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET). *Cancer Res* 15 February 2022; 82 (4\_Supplement): P5–13–22. <https://doi.org/10.1158/1538-7445.SABCS21-P5-13-22>
41. Giridhar KV, Sokol ES, Vedell PT, Sinnwell JP, Desai A, Haddad TC, O'Sullivan CC, **Leon-Ferre RA**, Yadav S, Sideras K, Ernst B, Liu MC, Eyman Casey A, Tang X, Fleischmann Z, Murugesan K, Kalari KR, Goetz MP; Abstract P3-08-02: The frequency and somatic mutation landscape of Fibroblast growth factor receptor (*FGFR*) alterations in breast cancer. *Cancer Res* 15 February 2022; 82 (4\_Supplement): P3–08–02. <https://doi.org/10.1158/1538-7445.SABCS21-P3-08-02>
42. Kalari KR, Thompson KJ, Sinnwell J, Tang X, Suman VJ, He J, Kee Byeon S, Pandey A, Eyman Casey A, Vedell PT, Moyer AM, Moreno-Aspitia A, Northfelt DW, Liu MC, Haddad TC, Chumsri S, Peethambaram P, Ruddy KJ, Giridhar KV, **Leon-Ferre RA**, Weinshilboum RM, Wang L, O' Sullivan CC, Goetz MP; Abstract P4-01-03: Multiomics data reveal novel biomarkers for CDK4/6 resistance. *Cancer Res* 15 February 2022; 82 (4\_Supplement): P4–01–03. <https://doi.org/10.1158/1538-7445.SABCS21-P4-01-03>

### Letters

1. Yadav S, Karam D, Bin Riaz I, Xie H, Durani U, Duma N, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Couch FJ, **Leon Ferre RA**, Ruddy KJ. Reply to On the proportion of male breast cancer among all breast cancers. *Cancer* 2020 Jan 1; 126 (9):2034-2035 Epub 2020 Feb 03 PMID:32012222 DOI:10.1002/cncr.32727

\* Indicates that the primary author was a mentee of this author.